Moderna’s mRNA flu vaccine faces FDA advisory panel scrutiny

Moderna is currently facing a review by an FDA advisory panel regarding its mRNA flu vaccine. This regulatory scrutiny has led to a rise in Moderna stock prices as investors react to the ongoing evaluation process. The panel is tasked with examining the vaccine's data to determine its viability. Market movements reflect the significance of this FDA review for the company's product pipeline and its potential impact on future healthcare delivery.